Residency · Irvine, CA
Sponsored by University of California (Irvine)
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum but evades most convalescent serum and therapeutic antibodies.
Science translational medicine · 2022 · 82 citations · Monique Hollis-Perry
Adverse Effects and Antibody Titers in Response to the BNT162b2 mRNA COVID-19 Vaccine in a Prospective Study of Healthcare Workers.
Open forum infectious diseases · 2022 · 64 citations · Monique Hollis-Perry
The Future of Occupational and Environmental Medicine.
Journal of occupational and environmental medicine · 2022 · 17 citations · Alya Khan
Antigenic cartography of well-characterized human sera shows SARS-CoV-2 neutralization differences based on infection and vaccination history.
Cell host & microbe · 2022 · 57 citations · Monique Hollis-Perry
Durability of Antibody Response and Frequency of SARS-CoV-2 Infection 6 Months after COVID-19 Vaccination in Healthcare Workers.
Emerging infectious diseases · 2022 · 30 citations · Monique Hollis-Perry
Natural killer cells and BNT162b2 mRNA vaccine reactogenicity and durability.
Frontiers in immunology · 2023 · 14 citations · Monique Hollis-Perry
SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster.
bioRxiv : the preprint server for biology · 2021 · 31 citations · Monique Hollis-Perry
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
PloS one · 2022 · 15 citations · Monique Hollis-Perry